Fenoldopam: A review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies

Drugs

Volumn 54, Issue 4, 1997, Pages 634-650

  Brogden, Rex N ^a   Markham, Anthony ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FENOLDOPAM; NITROPRUSSIDE SODIUM; PARACETAMOL;

ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ASTHENIA; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIURESIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; FLUSHING; HEADACHE; HEART LEFT VENTRICLE FUNCTION; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BLOOD FLOW; LIVER DISEASE; MAJOR CLINICAL STUDY; META ANALYSIS; NATRIURESIS; NAUSEA; NONHUMAN; REVIEW; SINUS BRADYCARDIA; VASODILATATION; VERTIGO;

EID: 0030706164     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199754040-00008     Document Type: Review

References (86)

1. Jin X-H, Wang W-Z, Zhao R-R. Comparison of the characteristics and density of dopamine-1 receptors in membranes from different arteries using [3H]SCH23390 binding. Methods Find Exp Clin Pharmacol 1995 Sep; 17: 455-61
2. 1) dopamine receptors in rat kidney. J Auton Pharmacol 1984 Dec; 4: 273-7
3. Ohlstein EH, Znbko-Polapovich B, Berkowitz BA. Studies on vascular dopamine receptors with the dopamine receptor agonist: SK∓F 82526. J Pharmacol Exp Ther 1984 May; 229: 433-9
4. 1-dopamine-receplor agonist and α-adrenoceptor antagonist activity of fenoldopam in the anesthetized dog. J Cardiovasc Pharmacol 1988 Jan; 11: 123-6
5. Lokhandwala MF, Watkins HO, Sabouni MH, et al. Pharmacological analysis of the actions of SKF 82526 on cardiovascular dopamine receptors. J Pharmacol Exp Ther 1985 Aug; 234: 337-44
6. Dupont AG, Lefebvre RA, Vanderniepen P. Influence of the dopamine receptor agonists fenoldopam and quinpirole in the rat superior mesenteric vascular bed. Br J Pharmacol 1987 Jul; 91: 493-501
7. 1) receptor agonist, on isolated human arteries. Blood Vessels 1989 Mar-Apr; 26: 119-27
8. 2adrenoceplor antagonist. Eur J Pharmacol 1985 Dec 3; 118: 321-9
9. 1 agonist. J Pharm Pharmacol 1986 Feb; 38: 113-7
10. Murphy MB, Weber RR, Nelson K, et al. The role of α-adrenoceptor blockade in the antihypertensive effects of fenoldopam in humans. Clin Pharmacol Ther 1988 Jul; 44: 49-55
11. Allison NL, Dubb JW, Ziemniak JA, et al. The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics. Clin Pharmacol Ther 1987 Mar; 41: 282-8
12. Taylor A, Luther RR, Fellmann J, et al. Pharmacodynamics of prolonged infusions of fenoldopam in patients with moder- ately severe hypertension [abstract]. J Clin Pharmacol 1995 Sep; 35:932
13. Elliott WJ, Weber R, Nelson KS, et al. Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension. Circulation 1990 Mar; 81: 970-7
14. Miranda B, Ruilope LM, Ciarcia-Robles R, et al. Effects of intravenous administration of fenoldopam on blood pressure and renal function in severe arterial hypertension [in SPAN1SH]. Med Clin Bare 1988 Oct 15; 91: 445-8
15. White WB, Radford MJ, Gonzalez FM, et al. Selective dopamine-1 agonist therapy in severe hypertension: effects of intravenous fenoldopam. J Am Coll Cardiol 1988 May; 11: 1118-23
16. Bodmann KF, Tröster S, Clemens R, et al. Hemodynamic profile of intravenous fenoldopam in patients with hypertensive crisis. Clin Investig 1993 Dec; 72: 60-4
17. Taylor AA, Mangoo-Karim R, Luther R, et al. Dose-dependent hemodynamic and renal effects of fenoldopam during prolonged inlusions in hypertensive patients [abstract]. Am J Hypertens 1996 Apr: 9 (Pt 2): 147
18. Vlavianos P, Polson RJ, Settin A, et al. Haemodynamic and pharmacokinetic study of intravenous fenoldopam in patients with hepatic cirrhosis. Br J Clin Pharmacol 1990 Jan; 29: 19-25
19. Zhao R-R, Wang P-H, Zhang W-F, et al. Analysis of the effects of dopainine-1 and dopamine-2 receptor agonists on coronary flow. Methods Find Exp Clin Pharmacol 1992 Jan-Feh; 14: 5-11
20. 2 receptor agonists on coronary and peripheral hemodynamics. Eur J Pharmacol 1990 Nov 6; 190: 193-202
21. Shi Y, Zalewski A, Bravette B, et al. Selective dopamine-1 receptor agonist augments regional blood flow: comparison of fenoldopam and dopamine. Am Heart J 1992 Aug; 124: 418-23
22. Greller DD, Clock D, Murphy MB. Acute blood pressure reduction with fenoldopam vs nitroprusside: effects on coronary blood flow [abstract]. J Hypertens 1992 Jun; 10 Suppl. 4: 222
23. Lappe RW, Todt JA, Wendt RL. Effects of fenoldopam on regional vascular resistance in conscious spontaneously hypertensive rats. J Pharmacol Exp Ther 1986 Jan; 236: 187-91
24. Redman D, Thorn SA, Hughes AD, et al. Human vasodilator responses to a dopamine agonist: possible mechanisms. J Hyperlens Suppl 1985 Dec; 3 Suppl 3: S177-8
25. Hackman BB, Griffin B, Mills M, et al. Comparative effects of fenoldopam mesylate and nitroprusside on left ventricular performance in severe systemic hypertension. Am J Cardiol 1992 Apr 1; 69: 918-22
26. Aronson S, Goldberg LI, Glock D, et al. Effects of fenoldopam on renal blood flow and systemic hemodynamics during isoflurane anesthesia. J Cardiothorac Vasc Anesth 1991 Feb; 5: 29-32
27. Dlewati A, Lokhandwala F. Dose-response analysis of the effects of fenoldopam, a dopamine-1 receptor agonist, on renal function. Drug Dev Res 1991: 22 (1): 59-68
28. Brooks DP, Goldstein R, Koster PF, et al. Effect of fenoldopam in dogs with spontaneous renal insufficiency. Eur J Pharmacol 1990 Aug; 184: 195-9
29. 1-receptor blockade and angiotensin converting enzyme inhibition on the renal actions of fenoldopam in the anaesthetized dog. J Hypertens 1991 Dec; 9: 1143-50
30. Bhal S, Churchill M, Churchill P, et al. Renal effects of SK&F 82526 in anesthetized rats. Life Sci 1986 Apr; 38: 1565-71
31. Chen C, Lokhandwala MF. Potentiation by enalaprilat of fenoldopam-evoked natriuresis is due to blockade of intrarenal production of angiotensin-II in rats. Naunyn Schmiedebergs Arch Pharmacol 1995 Aug; 352: 194-200
32. Carey RM, Hughes JM. Selective renal dopamine-1 receptor stimulation in man. Clin Exp Hypertens A 1987; 9: 1009-20
33. Hughes JM, Beck TR, Rose CE Jr, et al. Selective dopamine-1 receptor stimulation produces natriuresis by a direct tubular action. J Hypertens Suppl 1986 Dec; 4: S106-8
34. Hughes JM, Beck TR, Rose CE Jr, et al. The effect of selective dopamine-1 receptor stimulation on renal and adrenal function in man. J Clin Endocrinol Metab 1988 Mar; 66: 518-25
35. Hughes JM, Ragsdale NV, Felder RA, et al. Diuresis and natriuresis during continuous dopamine-1 receptor stimulation. Hypertension 1988 Feb. 11 (2 Pt 2): 169-74
36. Bughi S, Horton R, Antonipillai I, et al. Comparison of dopamine and fenoldopam effects on renal blood flow and prostacyclin excretion in normal and essential hypertensive subjects. J Clin Endocrinol Metab 1989 Dec; 69: 1116-21
37. O'Connell DP, Ragsdale NV, Boyd DG, et al. Differential human renal tubular responses todopamine type I receptor stimulation are determined by blood pressure status. Hypertension 1997 Jan; 29: 115-22
38. Ruilope LM, Robles RG, Miranda B, et al. Renal effects of fenoldopam in refractory hypertension. J Hypertens 1988 Aug; 6: 665-9
39. 1 agonist fenoldopam. Circulation 1987 Dec; 76: 1312-8
40. Andres A, Garcia-Robles R, Alcazar JM, et al. Diuretic and natriuretic properties of fenoldopam in chronic renal failure. J Hypertens 1989 Dec; 7 Suppl. 6: 326-7
41. Smit AJ. Dopamine in chronic renal failure. Am J Hypertens 1990 Jun; 3 Suppl.: 75-7
42. Shusterman NH, Elliott WJ, White WB, Fenoldopam. but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. Am J Med 1993 Aug; 95: 161-8
43. Elliott WJ, Weber R, Nelson KS, et al. Intravenous fenoldopam improves renal function compared to nitroprusside during the acute treatment of severe hypertension [abstract]. Eur J Pharmacol 1990 Jul; 183: 833
44. Boesgaard S, Hagen C, Andersen AN, et al. Effect of fenoldopam, a dopamine D-1 receptor agonist, on pituitary, gonadal and thyroid hormone secretion. Clin Endocrinol Oxf 1989 Mar; 30: 231-9
45. Antonipillai I, Broers MI, Lang D. Evidence that specific dopamine-1 receptor activation is involved in dopamine-induced renin release. Hypertension 1989 May; 13: 463-8
46. 1 receptor stimulation. J Cardiovasc Pharmacol 1989 May; 13: 739-47
47. Girbes ARJ, Smit AJ, Meijer S, et al. Renal and endocrine effects of fenoldopam and metoclopramide in normal man. Nephron 1990 Oct; 56: 179-85
48. White WB, Halley SE. Comparative renal effects of intravenous administration of fenoldopam mesylate and sodium nitroprusside in patients with severe hypertension. Arch Intern Med 1989 Apr; 149: 870-4
49. MacDonald TM, Jeffrey RF, Freestone S, et al.. A single dose study of the effects of fenoldopam and enalapril in mild hypertension. Eur J Clin Pharmacol 1991 Mar; 40: 231-6
50. Gretler DD, Elliott WJ, Moscucci M, et al. Electrocardiographic changes during acute treatment of hypertensive emergencies with sodium nitroprusside or fenoldopam. Arch Intern Med 1992 Dec; 152: 2445-8
51. Boppana VK, Dolce KM, Cyronak MJ, et al. Simplified procedures for the determination of fenoldopam and its metabolites in human plasma by high-performance liquid chromatography with electrochemical detection: comparison of manual and robotic sample preparation methods. J Chromatogr 1989 Feb 24; 487: 385-99
52. Boppana VK, Heineman FC, Lynn RK, et al. Determination of fenoldopam (SK&F 82526) and its metabolites in human plasma and urine by high-performance liquid chromatography with electrochemical detection. J Chromatogr 1984 Dec28; 317: 463-74
53. Osborne VL, Randolph WC. Analysis of SK&F 82526 in plasma by high-performance liquid Chromatography with electrochemical detection. J Chromatogr 1983 Jan 21; 255: 491-6
54. 1-receptor agonist, in hypertensive patients. Br J Clin Pharmacol 1988 Jan; 25: 17-21
55. 1 agonist, fenoldopam [abstract]. Clin Pharmacol Ther 1987; 41 (February): 236
56. Flaharty KK, Boyle DA, Smith DA, et al. Pharmacokinetic evaluations of fenoldopam following intravenous infusion and oral administration in elderly patients with congestive heart failure [abstract]. Pharmacotherapy 1991; 11 (3): 278
57. Blanchett DG, Green JA, Nara A, et al. The effect of food on pharmacokinetics and pharmacodynamics of fenoldopam in class III heart failure. Clin Pharmacol Ther 1991 Apr; 49: 449-56
58. Clancy A, Locke-Haydon J, Cregeen RJ, et al. Effect of concomitant food intake on absorption kinetics of fenoldopam (SK&F 82526) in healthy volunteers. Eur J Clin Pharmacol 1987; 32: 103-6
59. Ziemniak JA, Boppana VK, Cyronak MJ, et al. A retrospective analysis of fenoldopam renal excretion in 65 subjects: evidence for possible intrarenal formation of fenoldopam from its metabolites. Pharm Res 1989 Aug; 6: 702-5
60. Ziemniak JA, Boppana VK, Cyronak MJ, et al. Continuous intragastric delivery of fenoldopam: relationship between plasma concentration and effects on renal function. Br J Clin Pharmacol 1988 Mar; 25: 367-73
61. Klecker RW, Collins JM. Stereo-selective metabolism of fenoldopam and its metabolites in human liver microsomes, cytosol and slices [abstract]. Ninety-eighth annual meeting of the American Society for Clinical Pharmacology and Therapeutics 1997; 209, San Diego, Mar 5-8
62. Taylor AA, Polvino W, Shepherd A. A pharmacodynamic and pharmacokinetic study of tintravenous fenoldopam in hypertensive patients. Neurex Corporation (California) data on file. 94-005; June 13, 1996
63. Pool JL. A pharmacodynamic and pharmacokinetic pilot study of intravenous fenoldopam in patients with moderate to se- vere hypertension. Neurex Corporation (California) data on file. 94-007; June 13, 1996
64. Panacek EA, Bednarczyk EM, Dunbar LM, et al. Randomized, prospective trial of fenoldopam vs sodium nitroprusside in the treatment of acute severe hypertension. Acad Emerg Med 1995 Nov; 2: 959-65
65. Krakauer K. Single-blind study to compare the effect of intravenous administration of fenoldopam vs. nifedipine on post-operative hypertension and postoperative renal function in cardiac surgery patients. Neurex Corporation (California) data on file. COR CL0005; April 13, 1996
66. Bednarczyk EM, White WB, Munger MA, et al. Comparative acute blood pressure reduction from intravenous fenoldopam mesylate versus sodium nitroprusside in severe systemic hypertension. Am J Cardiol 1989 Apr 15; 63: 993-6
67. Pilmer BL, Green JA, Panacek EA, et al. Fenoldopam mesylate versus sodium nitroprusside in the acute management of severe systemic hypertension. J Clin Pharmacol 1993 Jun; 33: 549-53
68. Reisin E, Huth MM, Nguyen BP. Intravenous fenoldopam versus sodium nitroprusside in patients with severe hypertension. Hypertension 1990 Feb; 15 Suppl.: 59-62
69. White WB, Halley SE, Clemens R, et al. Comparison of the blood pressure lowering effects of fenoldopam and sodium nitroprusside in patients with severe hypertension [in German]. Nieren Hoch 1991 Oct; 20: 575-6
70. Munger MA, Rutherford WF, Anderson L, et al. Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension. Crit Care Med 1990 May; 18: 502-4
71. Gal TJ, Coaperman LH. Hypertension in the immediate post-operative period. Br J Anaesth 1975; 47: 70-4
72. Towne JB, Bernhard VM. The relationship of postoperative hypertension to complications following carotid endarterectomy. Surgery 1980; 88: 575-80
73. Leslie JB. Incidence and aetiology of perioperative hypertension. Acta Anaesthesiol Scand 1993; 37 Suppl. 99: 5-9
74. Viljoen JF, Estafanous FG, Tarazi RC. Acute hypertension immediately after coronary artery surgery. J Thorac Cardiovasc Surg 1976; 71: 548-50
75. Goldberg ME, Cantillo J, Nemiroff MS, et al. Fenoldopam infusion for the treatment of postoperative hypertension. J Clin Anesth 1993 Sep-Oct; 5: 386-91
76. Hill AJ, Feneck RO, Walesby RK. A comparison of fenoldopam and nitroprusside in the control of hypertension following coronary artery surgery. J Cardiothorac Vasc Anesth 1993 Jun; 7: 279-84
77. Elliott WJ, Karnezis TA, Silverman RA, et al. Intraocular pressure increases with fenoldopam. but not nitroprusside. in hypertensive humans. Clin Pharmacol Ther 1991 Mar; 49: 285-93
78. Karnezis TA, Murphy MB, Weber RR, et al. Effects of selective dopamine-1 receptor activation on intraocular pressure in man. Exp Eye Res 1988 Nov; 47: 689-97
79. Everitt DE, Boike SC, Piltz-Seymour JR, et al. Effect of intravenous fenoldopam on intraocular pressure in ocular hypertension. J Clin Pharmacol 1997 Apr; 37: 312-20
80. Ziemniak JA, Allison N, Boppana VK, et al. The effect of acetaminophen on the disposition of fenoldopam: competition for sulfation. Clin Pharmacol Ther 1987 Mar; 41: 275-81
81. Strocehi E, Taratgni F, Malini PL, et al. Interaction study of fenoldopam - digoxin in congestive heart failure. Eur J Clin Pharmacol 1989 Oct; 37: 395-7
82. Shao Z, Pania S, Yaacoub A, et al. Attenuation of the vascular effects of DA-1 receptor agonist, fenoldopam, by allopurinol [abstract]. Am J Hypertens 1992 May; 5 (Pt 2): 121A
83. Just VL, Schrader BJ, Paloucek FP, et al. revaluation of drug therapy for the treatment of hypertensive urgencies in the emergency department. Am J Emerg Med 1991; 9: 107-11
84. Abdelwahab W, Frishman W, Landau A. Management of hypertensive urgencies and emergencies. J Clin Pharmacol 1995 Aug; 35: 747-62
85. Kaplan NM. Management of hypertensive emergencies. Lancet 1994 Nov 12; 344: 1335-8
86. Hirschl MM. Guidelines for the drug treatment of hypertensive crises. Drugs 1995 Dec; 50: 991-1000